StreetInsider.com News Articles

Form 4 Artiva Biotherapeutics, For: Jul 21 Filed by: RA Capital Healthcare Fund LP

Thu, 23 Jul 2026 21:23:00 -0400

si-local-file:///var/storage/secattach/20260723/26809426.html

Form 4 Artiva Biotherapeutics, For: Jul 21 Filed by: RA Capital Healthcare Fund LP

Thu, 23 Jul 2026 21:23:00 -0400

si-local-file:///var/storage/secattach/20260723/26809426.html

Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Thu, 23 Jul 2026 21:23:00 -0400

si-local-file:///var/storage/secattach/20260723/26809427.html

Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Thu, 23 Jul 2026 21:23:00 -0400

si-local-file:///var/storage/secattach/20260723/26809427.html

Form 4/A Artiva Biotherapeutics, For: Jul 13 Filed by: RA Capital Healthcare Fund LP

Thu, 23 Jul 2026 21:21:00 -0400

si-local-file:///var/storage/secattach/20260723/26809424.html

Form 4/A Artiva Biotherapeutics, For: Jul 13 Filed by: RA Capital Healthcare Fund LP

Thu, 23 Jul 2026 21:21:00 -0400

si-local-file:///var/storage/secattach/20260723/26809424.html

Form 8-K Artiva Biotherapeutics, For: Jul 22

Wed, 22 Jul 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260722/26802675.html

Form 8-K Artiva Biotherapeutics, For: Jul 22

Wed, 22 Jul 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260722/26802675.html

Form 4 Artiva Biotherapeutics, For: Jul 16 Filed by: RA Capital Nexus Fund, L.P.

Mon, 20 Jul 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260720/26790645.html

Form 4 Artiva Biotherapeutics, For: Jul 16 Filed by: RA Capital Nexus Fund, L.P.

Mon, 20 Jul 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260720/26790645.html

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 07:30:00 -0400

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the “Inducement Grants”) for 17 new employees.

The Inducement Grants were granted pursuant to Artiva’s 2025 Inducement Plan (the “Inducement Plan”), and were effective July 14, 2026. The Inducement Grants will vest over four years, with vesting aligned to

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 07:30:00 -0400

Form 4 Artiva Biotherapeutics, For: Jul 10 Filed by: RA Capital Nexus Fund, L.P.

Tue, 14 Jul 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260714/26769367.html

Form 4 Artiva Biotherapeutics, For: Jul 10 Filed by: RA Capital Nexus Fund, L.P.

Tue, 14 Jul 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260714/26769367.html

Form 4 Artiva Biotherapeutics, For: Jun 25 Filed by: RA Capital Nexus Fund, L.P.

Mon, 29 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260629/26706743.html

Form 4 Artiva Biotherapeutics, For: Jun 25 Filed by: RA Capital Nexus Fund, L.P.

Mon, 29 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260629/26706743.html

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Tue, 23 Jun 2026 16:05:00 -0400

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 3:30 pm EDT.

To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Tue, 23 Jun 2026 16:05:00 -0400

To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will

Form 4 Artiva Biotherapeutics, For: Jun 12 Filed by: RA Capital Nexus Fund, L.P.

Tue, 16 Jun 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26655531.html

Form 4 Artiva Biotherapeutics, For: Jun 12 Filed by: RA Capital Nexus Fund, L.P.

Tue, 16 Jun 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26655531.html

Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 15 Jun 2026 19:37:00 -0400

si-local-file:///var/storage/secattach/20260615/26649048.html

Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 15 Jun 2026 19:37:00 -0400

si-local-file:///var/storage/secattach/20260615/26649048.html

Form 4 Artiva Biotherapeutics, For: Jun 09 Filed by: RA Capital Nexus Fund, L.P.

Thu, 11 Jun 2026 19:36:00 -0400

si-local-file:///var/storage/secattach/20260611/26637177.html

Form 4 Artiva Biotherapeutics, For: Jun 09 Filed by: RA Capital Nexus Fund, L.P.

Thu, 11 Jun 2026 19:36:00 -0400

si-local-file:///var/storage/secattach/20260611/26637177.html

Artiva receives FDA RMAT designation for rheumatoid arthritis therapy

Mon, 08 Jun 2026 06:30:50 -0400

Artiva Biotherapeutics Inc. (NASDAQ: ARTV) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to its AlloNK therapy combined with rituximab for treating refractory rheumatoid arthritis.

The San Diego-based biotechnology company presented clinical data for AlloNK at the European Alliance of Associations for Rheumatology 2026 Congress in London. The therapy is an allogeneic, off-the-shelf natural killer cell treatment designed to enhance antibody-dependent cellular cytotoxicity when combined with monoclonal antibodies.

In the company-sponsored Phase 2a basket trial, 71% of rheumatoid arthritis patients with six months of follow-up achieved an ACR50 response, according to data with an April 3,